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Despite the importance of vaccinia virus in basic and applied immunology, our knowledge of the human immune
response directed against this virus is very limited. CD4
þ T cell responses are an important component of immunity
induced by current vaccinia-based vaccines, and likely will be required for new subunit vaccine approaches, but to date
vaccinia-specific CD4
þ T cell responses have been poorly characterized, and CD4
þ T cell epitopes have been reported
only recently. Classical approaches used to identify T cell epitopes are not practical for large genomes like vaccinia. We
developed and validated a highly efficient computational approach that combines prediction of class II MHC-peptide
binding activity with prediction of antigen processing and presentation. Using this approach and screening only 36
peptides, we identified 25 epitopes recognized by T cells from vaccinia-immune individuals. Although the predictions
were made for HLA-DR1, eight of the peptides were recognized by donors of multiple haplotypes. T cell responses were
observed in samples of peripheral blood obtained many years after primary vaccination, and were amplified after
booster immunization. Peptides recognized by multiple donors are highly conserved across the poxvirus family,
including variola, the causative agent of smallpox, and may be useful in development of a new generation of smallpox
vaccines and in the analysis of the immune response elicited to vaccinia virus. Moreover, the epitope identification
approach developed here should find application to other large-genome pathogens.
Citation: Calvo-Calle JM, Strug I, Nastke MD, Baker SP, Stern LJ (2007) Human CD4
þT cell epitopes from vaccinia virus induced by vaccination or infection. PLoS Pathog 3(10):
e144. doi:10.1371/journal.ppat.0030144
Introduction
Immunization with vaccinia virus elicits long-lasting
cellular and humoral immune responses in humans and in
animal models (reviewed in [1]). A main component of the
protective immune response elicited by this virus are
neutralizing antibodies [2]. The importance of antibodies in
immunity to poxviruses has been shown by passive transfer of
antibodies in rodent and primate models challenged with
variola virus orthologs [3,4]. B cell–deﬁcient mice challenged
with ectromelia, an Orthopoxvirus member of the same genus
as the human smallpox pathogen variola, do not recover from
a primary infection despite a strong CD8
þ T cell response [5],
suggesting that antibodies are an obligatory requirement for
recovery of a primary poxvirus infection [3,6]. Protective
antibody responses to poxvirus in mice seem to be T cell
dependent [7] and require, in addition to B cells, major
histocompatibility complex (MHC) class II molecules and
CD40 during a secondary infection [6]. CD4
þ T cells are also
required for the generation of optimal anti-vaccinia CD8
þ T
cell responses [8]. Since protective antibody responses to
poxvirus could also be elicited by immunization with single or
multiple proteins in mice and in primate models [9–12], or by
transfer of monoclonal or polyclonal antibodies to deﬁned
protein components [10,13,14], development of subunit
vaccines would appear to be feasible and will require the
characterization of CD4
þ T cell epitopes capable of generat-
ing long-lasting antibody responses. Although human poly-
clonal CD4
þ T cell responses to vaccinia virus have been
documented [7,15,16], only recently have vaccinia-speciﬁc
CD4
þT cell epitopes been reported, by Tang et al. [17], Jing et
al. [18], and Mitra-Kaushik et al. [19] in humans and by
Moutaftsi et al. [20] in a mouse model. Tang et al. identiﬁed
three CD4
þ T cell epitopes in the A27L protein by screening
with a series of overlapping peptides covering the entire
protein sequence [17]. Jing et al. followed a more compre-
hensive approach by screening a vaccinia genomic library
that resulted in the identiﬁcation of 44 separated antigenic
regions of various sizes [18]. Mitra-Kaushik and collaborators
approached the identiﬁcation of CD4
þ T cell epitopes in
vaccinia by screening a set of 36 peptides predicted by the
computational approach (described here), resulting in the
identiﬁcation of the ﬁrst two cytotoxic HLA-DR1-restricted
CD4
þ T cell epitopes in vaccinia. In the animal model,
Moutaftsi et al. screened 2,146 peptides and identiﬁed 14
epitopes restricted by the MHC molecule I-A
b. The two large-
scale screenings, by Jing et al. in humans and by Moutaftsi et
al. in mice, suggest that the CD4
þ T cell response to vaccinia
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þT cell response, is directed against a large
number of proteins. Interestingly, there is a little overlap in
the T cell epitopes mapped in these studies.
Computational approaches can be used to reduce the
number of potential CD4
þ T cell epitopes to be tested. The
mode of interaction of peptide antigens with class II MHC
proteins is well understood from structural studies of MHC–
peptide complexes and from biochemical investigation of the
interaction [21], and several algorithms have been presented
to predict peptide binding to particular class II MHC
proteins. Most of these are based on position-speciﬁc scoring
matrices or peptide binding ‘‘motifs’’, which evaluate the
probability of peptide binding and/or presentation by
assigning a value for each amino acid at each position in a
nine- or ten-residue binding frame. This approach is based
on the observation that class II MHC-bound peptides adopt a
conserved extended conformation with peptide side chains at
certain positions binding independently into allele-speciﬁc
pockets in the binding site [21]. Values for the relative
contribution of each amino acid side chain at each position
in a bound peptide have been evaluated by quantitative
binding assays [22,23], library screening approaches [24,25],
and analysis of the pool of endogenously bound peptides
[26,27]. Non-matrix-based neural network and hidden Mar-
kov model binding prediction algorithms also have been
presented [28–30]. However, progress in identifying class II
MHC-restricted CD4
þ T cell epitopes has been limited by the
relatively poor prognostic ability of available peptide binding
prediction algorithms, and the consequent need to screen
large sets of potential epitopes. Epitope prediction algo-
rithms for class II MHC proteins usually are estimated to be
only approximately 50% accurate [31–33]. This low predic-
tion ability has led many investigators to forego epitope
prediction entirely, and instead test a comprehensive series
of overlapping peptides completely covering the protein(s) of
interest. For vaccinia this would require analysis of .3,000
peptides.
In this work we have combined aspects of previous epitope
prediction approaches, and developed an efﬁcient procedure
for identifying potential HLA-DR-restricted CD4
þ T cell
epitopes. We observed interferon-c (IFN-c) responses to 25
out of 36 peptides predicted to contain CD4
þ T cell epitopes.
T cells recognizing these peptide sequences were observed in
blood samples obtained from donors many years after
exposure to the vaccinia virus, and some were expanded in
response to booster vaccination, suggesting that these cells
contribute to the long-lasting memory T cell response elicited
by vaccinia virus [16]. In addition, most of the epitopes were
conserved across many Poxviridae species, including variola.
Eight peptide sequences were recognized by multiple
vaccinia-exposed donors, making them ideal candidates for
tracking immunity elicited by vaccination or for inclusion in
subunit vaccines for this important virus family.
Results
Evaluation of Epitope Prediction Algorithms
Although several algorithms have been described for
prediction of HLA-DR-restricted T cell epitopes, these have
not been comprehensively evaluated nor compared for their
relative predictive ability (a comparison of two algorithms has
appeared [31]). One complication to such evaluation is that
the epitope prediction algorithms generally consider only the
nine to 11 residues in contact with the MHC, whereas most T
cell epitope identiﬁcation studies use longer peptides, within
which the actual MHC binding register is not known. For
evaluation of the available DR-restricted T cell epitope
prediction algorithms, we selected as test antigens a series
of 18 well-characterized T cell epitopes restricted by HLA-
DR1 (DRB1*0101), using the Syfpeithi [33] and IEDB [34] T
cell epitope databases. The protein sources for these epitopes
include viral, bacterial, and tumor antigens, ranging in length
from ;200 to .3,000 residues. HLA-DR1, a common human
class II allotype, has been the focus of much biochemical
characterization, and for four of the test epitopes, the
peptide binding register has been determined unambiguously
by published crystallographic, biochemical, and peptide
truncation studies (Table 1). For the other epitopes, the
binding register was not as precisely deﬁned, having been
localized to a short 11- to 18-residue minimal peptide
sequence by published truncation or mutagenesis studies
(Table 1). In every case we required that the epitope peptide
had been observed to be immunodominant or co-immuno-
dominant among other potential epitopes derived from the
same protein, by analysis of an overlapping peptide series or
by characterization of naturally processed peptides.
We evaluated nine prediction algorithms for their ability to
predict these test epitopes. These algorithms span the variety
of approaches applied to this problem, including position-
speciﬁc scoring matrices derived from in vitro peptide
binding data (‘‘P9’’, ‘‘P10’’, ‘‘Epimmune’’, ‘‘IEDB’’), from
random peptide library screening (‘‘undec’’), from character-
ization of endogenously processed peptides (‘‘Syfpeithi’’), and
from bionformatic analysis of known T cell epitopes
(Rankpep), and also non-matrix-based artiﬁcial neural net-
work (‘‘ANN’’) and hidden Markov model (‘‘HMM’’) algo-
rithms (Table 1). Most algorithms considered potential nine-
residue binding frames, but one considered ten residues (P10)
and one 11 (undec). For each algorithm, we scored every
potential epitope present in the protein of interest, and
compared these predictions to the actual immunodominant
T cell epitopes found experimentally. The rank of the
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Author Summary
Although the routine use of vaccinia virus for vaccination against
smallpox was stopped after eradication of this disease, there is a
possibility for an accidental or intentional release of this virus. In
response to this challenge, vaccination of at least emergency
personnel has been suggested. However, adverse reactions induced
by the smallpox vaccine have had a negative impact in the success
of this program. For these reasons development of new smallpox
vaccines is a public health priority. Identification of strong helper T
cell epitopes is central to these efforts. However, identification of T
cell epitopes in large genomes like vaccinia is difficult using current
screening methods. In this work, we develop a new computational
approach for prediction of T cell epitopes, validate it using epitopes
already identified by classical methods, and apply it to the
prediction of vaccinia epitopes. Twenty-five of 36 peptides
containing predicted sequences were recognized by T cells from
individuals exposed to vaccinia virus. These peptides are highly
conserved across the orthopox virus family and may be useful in
development of a new generation of smallpox vaccines and in the
analysis of the immune response against vaccinia virus.immunodominant epitope(s) among all the potential epitopes
present in each protein is shown in Table 1. Each of the
algorithms tested was successful in predicting the exper-
imentally observed T cell epitopes. The performance of the
algorithms varied, as shown by the average rank percentile
values shown in Table 1. For the most efﬁcient algorithms, the
scores of the experimentally determined epitopes were found
in the top ;1%–2% of all potential binding frames (Table 1).
However, even for the least efﬁcient algorithms, the
immunodominant epitopes generally were found within the
top 10% (Table 1).
In addition to the ranking analysis, which evaluates the
ability of the algorithms to identify the actual immunodo-
minant epitope among the top scoring epitopes, we also
performed receiver-operating characteristic (ROC) analysis
[35,36], which evaluates the prediction of true positives versus
false positives as the discrimination threshold is varied [37].
ROC curves were determined for each algorithm, treating the
entire set of protein antigens and known immunodominant
epitopes as a single test set (Figure S1). The area under the
ROC curve is a measure of the probability that a randomly
selected true positive will have a higher predicted score than
a randomly selected true negative [37]; these values are shown
in Table 1. As in the ranking analysis, each of the algorithms
was able to predict the observed immunodominant epitopes
far better than a random prediction (AUC ROC ¼ 0.5).
Similar trends were observed in the relative predictive power
of the different algorithms as measured by ranking or ROC
analysis (Table 1).
Based on ranking and ROC analysis, we selected the two
top scoring algorithms (P9 and Syfpeithi) for further work.
The P9 algorithm is based on an approach pioneered by
Table 1. Comparison of Epitope Prediction Algorithms Using Known DR1-Restricted T Cell Epitopes
Source
Protein
Immunodominant
Epitope
a
Total Number
of Epitopes
b
Predicted Rank of Immunodominant Epitope among All Possible Epitopes
Syfpeithi P9 P10
c IEDB ANN Rankpep HMM Epimmune Undeca
d
Influenza Ha YVKQNTLKL 558 2 4 3 1 16 4 22 3 129
Human TPI IGILNAAKV 241 1 1 2 6 12 3 27 4 1
HIV-gag VIPMFSALS 234 10 12 13 5 24 27 41 11 56
Tetanus toxin YIKANSKFI 1306 24 21 10 5 59 91 88 86 283
N.mening omp EFGTLRAGRVA 373 1 7 6 1 8 5 5 13 1
EBV EBNA SLYNLRRGTAL 196 2 10 5 3
aa 71 2 6 6
aa 2
aa
Dengue poly GFRKEIGRMLN 3,379 20 4 45 126 608 16 1041 221
bb 499
HCV poly LFNILGGWVA 2,931 1 8 5 48 92 221 26 644
cc 31
cc
HCV poly LVNLLPAILS 2,931 11 9
dd 22 35 96 33 119 181 16
EBV BZLF QHYREVAAAKSSE 237 1 4 5 2 15 1 34 61
ee 7
M.lepr Hsp65 LEDPYEKIGAEIVKE 532 1 9 5 4 27 28 82 30
ff 27
CMV pp65 LPLKMLNIPSINVH 554 8 4 8 13
hh 5
gg 50
gg 41
gg 19 22
hh
HIV-gag PIVQNIQCGMVHQ 234 5 5 11 13 27 28 68
nn 16
mm 18
nn
HIV-gag AEWDRVHPVHAG 234 5 18 12 74 68 29 6 167 42
HIV-gag NKIVRMYSPTSI 234 9 2
oo 1
oo 2
pp 2
oo 52
oo 14 1
HIV-gag QEQIGWMTNNPPIP 234 23 16 26 11
qq 55 219
rr 15 2
rr 23
rr
HIV-gag FRDYVDRFYKTLRAEQAS 234 1 4 8 1 17 1 25
jj 14 7
HIV-gag KRWIILGLNKIVRMVSP 234 4 1 3 2
kk 11 30
ll 10 38
ll 4
Average rank percentile 1.7 2.2 2.5 3.4 7.9 10.0 9.9 13.8 7.7
Standard error 0.5 0.5 0.6 1.9 2.1 5.0 2.0 4.0 4.0
Area under ROC curve 0.989 0.984 0.982 0.969 0.935 0.914 0.897 0.881 0.863
Standard error 0.003 0.003 0.004 0.013 0.013 0.035 0.021 0.027 0.042
Homogenous subsets
e 1 1,2 2 2 3 3,4 4 4 4
aThe consensus 9-mer binding frame is underlined in the sequence of the experimentally determined minimal peptide; exceptions noted below in notes aa–rr:
aaSLYNLRRGTAL.
bbGFRKEIGRMLN.
ccLFNILGGWVA.
ddLVNLLPAILS.
eeQHYREVAAAKSSE.
ffLEDPYEKIGAEIVKE.
ggLPLKMLNIPSINVH.
hhLPLKMLNIPSINVH.
iiLPLKMLNIPSINVH.
jjFRDYVDRFYKTLRAEQAS.
kkKRWIILGLNKIVRMVSP.
llKRWIILGLNKIVRMVSP.
mmPIVQNIQCGMVHQ.
nnPIVQNIQCGMVHQ.
ooNKIVRMYSPTSI.
ppNKIVRMYSPTSI.
qqQEQIGWMTNNPPIP.
rrQEQIGWMTNNPPI.
bTotal number of possible 9-mer epitopes in source protein.
cThis algorithm considers a 10-mer binding frame corresponding to the consensus 9-mer with an additional C-terminal residue.
dThis algorithm considers an 11-mer binding frame corresponding to the consensus 9-mer with one N-terminal and one C-terminal flanking residue.
eAlgorithms were grouped into four subsets based on 95% confidence intervals of the area under the ROC curve. Statistically undistinguished subsets have the same subunit number.
doi:10.1371/journal.ppat.0030144.t001
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quantitative peptide binding assays for a series of single
amino acid substitutions in test peptides, to predict relative
MHC–peptide binding afﬁnities [23,38]. We used a modiﬁca-
tion of the full nine-residue motif originally determined for
HLA-DR4 [23] by incorporating optimized side-chain pref-
erences for binding into the P1, P4, P6, and P9 pockets of
HLA-DR1 [25] (see Materials and Methods for details). We will
refer to the values from this prediction method as the
‘‘predicted binding score’’. The Syfpeithi algorithm, devel-
oped by Rammensee, Stevanovi c, and colleagues, relies on an
analysis of a database of naturally processed peptide
sequences found associated with particular MHC proteins,
to predict antigen processing and presentation [33]. We used
the processing and presentation prediction motifs as imple-
mented in the Syfpeithi server (http://www.syfpeithi.de/). We
will refer to the values from this method as the ‘‘predicted
antigen presentation score’’ (although the libraries of
naturally processed peptides used in this approach reﬂect
both binding and processing). The P9 and Syfpeithi algo-
rithms also have the advantage of being derived from datasets
independent of published T cell epitope work, including the
epitopes analyzed in Table 1. We reasoned that combining
scores from algorithms based on independent data sets would
complement the deﬁciencies in each approach and would
maximize the overall predictive power of epitope prediction.
In this combination approach, we considered epitopes that
were scored highly by both algorithms. We considered using a
single combined P9-Syfpeithi score, but instead we used a
two-dimensional plot analysis, so that potential epitopes
scoring highly in one algorithm but poorly with the other
could be easily identiﬁed and rejected.
We evaluated the combination approach in predicting the
same set of well-characterized HLA-DR1 T cell epitopes
described above. Dot plots of predicted peptide binding and
antigen presentation scores for each potential 9-mer epitope
are shown in Figure 1, with the actual epitope(s) present in
each protein shown by a solid symbol. In cases where the
binding frame within the known epitope was not completely
determined by crystallography or mutagenesis (Figure 1E–
1L), open symbols show the other potential binding frames.
In each case, the actual T cell epitopes were found in the
extreme upper-right region of the plot of all scores. These
results suggested that a combined predicted binding and
presentation approach would be useful in identifying MHC
class II-restricted T cell epitopes from vaccinia virus.
Identification of Potential Vaccinia Epitopes
We used the combined P9 binding and Syfpeithi presenta-
tion algorithms to predict DR1-restricted T cell epitopes
from the modiﬁed vaccinia Ankara (MVA) [39] strain of
vaccinia virus. Figure 2A shows a plot of the predicted P9
peptide binding and Syfpeithi antigen presentation scores
calculated for each of the 47,658 different 9-mer peptide
sequences present in predicted open-reading frames of the
genomic sequence. Thirty-six 9-mer sequences with high
scores in both algorithms were selected for continued analysis
(Figure 2A, inset). These cutoffs represent the top 0.4% and
1.1%, respectively, of all the predicted scores for the P9 and
Syfpeithi scores. For each sequence, a 21-mer peptide was
synthesized containing the 9-mer sequence of interest ﬂanked
by several residues on each side to allow for productive T cell
interaction with residues outside the direct MHC–peptide
contact region [40] (Table 2). HLA-DR1 binding to each of
these peptides was evaluated by a competition assay (Figure
2B; Table 2). For immunogenicity analysis, the peptides were
grouped according to the experimental IC50 values into seven
pools of three to six peptides (Figure 2B; Table 2). In this
manner we hoped to minimize inter-peptide competition
within a pool that could result in poor responses to peptides
with lower afﬁnities.
Analysis of CD4
þ T Cell Responses in a Vaccinated HLA-
DR1 Donor
To evaluate the presence of actual class II T cell epitopes in
the predicted set of peptides, we initially studied the T cell
responses in two HLA-DR1 (DRB1*0101) donors, one
previously immunized against smallpox approximately 35
years earlier (SL131) and one non-immunized and presum-
ably naı ¨ve with respect to vaccinia virus (SL127) (Table 3).
From previous studies of the human CD4
þ T cell response to
vaccinia, we expected that vaccinia-speciﬁc T cells would be
present at low frequency in an immunized donor [16], but
would be capable of antigen-driven expansion in vitro for
many years after exposure to the virus [16,41–43]. Thus, we
generated T cell lines (TCLs) from peripheral blood mono-
nuclear cell (PBMC) preparations from these donors by in
vitro expansion with a heat-inactivated lysate of CV-1 cells
infected with Dryvax vaccinia virus as a source of vaccinia
antigens [19]. Dryvax was the prevalent vaccine formulation
used for vaccination in the US up to the eradication of
smallpox worldwide in 1977. Figure 3A shows the IFN-c
ELISPOT response of TCLs from the two DR1 donors to the
pools of peptides presented in Table 2. There is a striking
difference in the recognition of peptide pools by these two
volunteers. The numbers of IFN-c-secreting cells responsive
to peptide pools 3, 4, and 5 in a TCL raised from the
immunized donor (dark bars) are ﬁve to 50 times larger than
the corresponding numbers in a line raised from the non-
immunized donor (gray bars).
The responses to peptide pools 3, 4, and 5 observed for the
immunized donor appear to represent a pool of long-lasting
memory T cells persisting for .35 years after Dryvax
immunization. If these responses were elicited by vaccination,
they should be boosted by a second re-immunization [43]. An
analysis of the IFN-c response of TCLs raised from PBMC
samples of the immunized donor obtained on days 7 and 13
after a second Dryvax dose demonstrated that responses to
pools 3, 4, and 5 are boosted by a second immunization and
also revealed T cell speciﬁcities to pool 1 and a weak response
to pools 2 and 7 not observed in the long-lasting memory
pool apparent before boosting (Figure 3B). Overall, re-
vaccination of this individual resulted in approximately a 2-
fold increase in the number of IFN-c-secreting cells recog-
nizing peptides in pools 3, 4, and 5, when compared to the
numbers observed in the TCL prior to boost, and also
resulted in a broadening of the response to include
recognition of peptide pools not observed prior to boost.
Extension to Other HLA-DR Haplotypes
The identiﬁcation of peptides presented by multiple MHC
class II haplotypes is an important goal of epitope discovery
efforts, and in this case could help efforts to induce and track
poxvirus immunity in a larger segment of the populations. In
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variety of proteins have been shown to be presented by
multiple class II MHC proteins [44–46]. This is a reﬂection of
the similarity of peptide binding preferences within the HLA-
DR family of alleles, all of which share a conserved alpha
subunit that contributes much of the surface area of the
important P1 and P9 pockets [47]. Moreover, HLA-DR1
(DRB1*0101) is considered an exemplar of a large fraction of
t h ee n t i r eH L A - D Rf a m i l y ,as most HLA-DR1-binding
peptides also bind well to other HLA-DR alleles [48,49]. For
example, each of the peptides in Table 1 is predicted by a
matrix-based binding algorithm [50] to bind to many differ-
ent alleles in the HLA-DR family, with a minimum of 11
Figure 1. Predicted Binding and Antigen Presentation Scores for Known HLA-DR1-Restricted T Cell Epitopes
(A–D) T cell epitopes for which the MHC-binding register has been definitively established. Filled circles (red) show 9-mer binding frames established by
crystallographic analysis or truncation and alanine scanning mutagenesis, black dots indicate all possible 9-mer epitopes present in the entire proteins.
(A–C) Binding frame identified by crystallographic analysis.
(A) HA(306–318) from influenza virus heamagglutinin (A/New AYork/383/2004(H3N2)) [47]; (B) mutated TPI(23–37) from human triose phophate
isomerase containing Ile instead of Thr at position 28 [77,78], with filled blue square indicating mutated peptide recognized as a tumor antigen; (C)
PP16 p24(161–181) from HIV-1 strain NY-5 gag p24 protein; (D) TT(830–843) from tetanus toxin [46]; (E–H) T cell epitopes identified by overlapping
peptides for which a small minimal peptide epitope has been characterized by truncation analysis. For each minimal peptide epitope, all of the possible
9-mer binding frames are shown as open circles, with the likely MHC binding frame, identified as a 9-residue sequence starting with a hydrophobic
residue near the N-terminus of the peptide [23,38,70], indicated by a filled symbol. (E) N. meningitidis outer membrane porin A protein (91–108) [79]; (F)
EBV nuclear antigen EBNA-1([78–88) [80]; (G) hepatitis C virus strain LIV23 polyprotein. Two epitopes have been characterized: NS4(1809–1817) and
NS4(1879–1888) [81], shown in red circles and in blue squares, respectively. For the NS4 epitope, the minimal 10-mer peptide contains two likely
binding frames, indicated by half-filled squares. (H) Dengue virus type 4 virus D4V capsid(84–92) [82]. (I–L) T cell epitopes identified by overlapping
peptide analysis with larger minimal peptides. As in (E–H), presumptive binding frames are indicated by solid symbols with other potential epitopes
from the same minimal peptide shown with open symbols. (I) HIV-1 (strain HXB2) p24 gag epitopes: AEWDRVHPVHAG(210–221) [83] in red circles;
NKIVRMYSPTSI(271–282) [83] in blue squares, as in (G) two possible binding frames are indicated with half-filled squares; HIV-1 (strain NY5) p24 gag
epitope PEVIPMFSALSEGATP(167–182) in green diamonds [84], for this epitope the binding frame is known exactly as shown in (C);
PIVQNIQGQMVHQ(133–145) in magenta up-facing triangles; QEQIGMTNNPPIP(244–256) [83] in cyan down-facing triangles; KRWIILGLN-
KIVRMVSP(264–280) [85,86] in brown left-facing triangles; FRDYVDRFYTLRAEQAS(294–311) in aquamarine right-facing triangles [86,87]. (J)
Mycobacterium leprae heat shock protein hsp65(61–75) [88]. (K) Human cytomegalovirus (strain AD169) pp65(115–127) [89], as above with two
potential binding frames shown in half-filled symbols, (L), EBV BZLF-1 protein(198–210) [90,91].
doi:10.1371/journal.ppat.0030144.g001
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HLA-DR alleles considered in the analysis (Table 2).
To evaluate the ability of the peptide pools to be
recognized by vaccinia-speciﬁc T cells in the context of other
HLA-DR alleles, we raised TCLs as above from blood samples
of ﬁve individuals with other haplotypes (Table 3). This
second group was highly heterogeneous with respect to their
MHC haplotypes, age, and exposure to the virus. Volunteers
SL101 and SL135 were immunized once and volunteer SL107
twice, volunteer SL136 was accidentally infected twice while
working with the Western reserve strain of vaccinia virus
(WR), and volunteer SL137 had no previous exposure to
vaccinia virus. TCLs from these donors were tested for their
ability to recognize the peptide pools as described above. In
spite of the variability in this group, TCLs raised from each of
the vaccinia exposed donors recognize pools 4 and 5 (Figure
3C); these pools were recognized best by the immunized DR1
donor (Figure 3A and 3B). Pool 3 was recognized by two of
the three immunized donors and by the infected donor
(SL136). Pools 2 and 6 were also recognized by three of four
vaccinia-exposed donors. Interestingly, only in the infected
donor did we observe a signiﬁcant response to pool 6. Pool 1
was recognized by T cells from only one of the immunized
donors, and pool 7 induced a higher number of IFN-c cells in
the non-immunized donor as observed also in the HLA-DR1
donors. Thus, despite the differences in MHC haplotype, the
vaccinia-exposed donors followed a similar pattern of
reactivity described above for the immunized DR1 donors.
The magnitude of the responses do not seem to correlate with
the number of doses in this small cohort of volunteers, since
donor SL135, immunized once, recognizes at a higher
frequency a larger number of pools than does donor SL107,
immunized twice (Table 3).
Figure 2. Prediction of Vaccinia-Derived HLA-DR1-Binding Peptides and Experimental Validation of Binding Affinity
(A) HLA-DR1 predicted binding score and predicted antigen presentation score for each 9-mer potential peptide epitope are indicated by dots. Circles
show peptides selected for further analysis (Table 1), filled circles indicate peptides for which T cell responses were observed. Inset shows high-scoring
region. High-scoring peptides that were not included in the study because of synthetic difficulty are indicated by x.
(B) Competition binding assay to evaluate MHC–peptide affinity. The ability of various concentrations of unlabelled MVA peptide to compete with
biotinylated test HA peptide for binding to recombinant soluble HLA-DR1 was determined. Values shown (error bars) represent average (standard
deviation) of three independent binding experiments. IC50 values were determined by fitting to a competition binding equation. Peptides were
grouped as indicated into seven pools based on observed IC50 values.
doi:10.1371/journal.ppat.0030144.g002
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Immunodominant CD4
þ T Cell Epitopes
To deﬁne the particular peptides recognized in a given
pool, TCLs from the responding donors were tested
separately with each of the individual peptides present in
the peptide pools (Figure 4). The overall analysis of the
response to individual peptides indicates that several of the
peptides are recognized by TCLs from multiple donors with
roughly similar patterns despite the differences in MHC
haplotypes, but also that the donors differ in the breadth of
their responses against these peptides.
Pool 1. This pool contains the peptides with the highest
relative afﬁnity for DRB1*0101 molecules and was recognized
at signiﬁcant levels by two of the four immunized donors, the
DR1
þ donor SL131 and donor SL135. We therefore studied
TCLs from these two donors and found that T cell responses
in this pool are directed mainly to peptide 345 (Figure 4A). A
second in vitro stimulation of these TCLs with the crude
preparation of heat-inactivated vaccinia virus reveals IFN-c
responses in SL131 to peptides 308, 314, and 327 (Figure S2).
Pool 2. Peptide pool 2 was recognized at a relatively low
level by some of the immunized volunteers and by the
infected donor. Since the infected donor’s (SL136) response
was three to six times higher than that of the other three
volunteers, we mapped the response only in SL136. In this
case the response to the peptide pool is directed to peptide
337 (Figure 4B). The remaining peptides in this pool do not
induce IFN-c responses even after a second in vitro
stimulation of the TCL (Figure S2).
Pool 3. This pool was consistently recognized by multiple
Table 2. Predicted HLA-DR-Restricted T Cell Epitopes from Vaccinia Virus
Peptide
a
(Pool)
Sequence
b,c Protein of
Origin
Binding Prediction
Score for HLA-DR1
Other HLA-DR
Predicted to Bind
d
IC50 (nM) Expressed
in Virion
e
Early/Late
Promoter
f
P9 Syfpethi
301(4) NTKEGRYLVLKAVKVCDVRTV
c F17R (15–35) 3.4 35 42 190 6 16 Y L
302(3) QTANVVFRYMSSEPIIFGESS D1R (401–421) 3.3 32 35 37 6 10 Y E
304(7) RPNSFWFVVVRAIASMIMYLV A9L (40–60) 2.9 33 51 4,000 6 150 Y L
305(2) IPLSEMVVKLTAVCMKCFKEA J2R (125–145) 2.8 35 45 29 6 10 nd E
306(1) ILKSLGFKVLDGSPISLRYGS I8R (240–260) 2.7 35 11 5 6 1Y L
307(2) TTKHPDYAILAARIAVSNLHK
c I4L (68–88) 2.5 38 31 28 6 4n d E L
308(1) NTSTREYLKLIGITAIMFATY F1L (198–218) 2.2 36 35 23 6 5n d E
310(6) RLVSRNYQMLLALVALVITLT
c L2R (60–80) 3.8 35 51 660 6 25 nd EL
g
311(7) CLVFEPFVNQSGIEILLLYFK D11L (382–402) 3.7 33 27 3,400 6 140 Y L
312(6) GTGVQFYMIVIGVIILAALFM L1R (181–201) 3.7 35 51 620 6 110 Y L
313(5) TNEFISFLLLTSIPIYNILFW E8R (122–142) 3.6 33 43 510 6 110 Y E/L
314(1) YIGQFDMRFLNSLAIHEKFDA I7L (189–209) 3.3 33 51 4 6 1Y L
316(3) NKNKIPFLLLSGSPITNTPNT D6R (154–174) 3.1 35 11 45 6 19 Y L
317(6) YMIVIGVIILAALFMYYAKRM L1R (187–207) 2.8 35 51 675 6 185 Y L
319(6) MRSLIIVLLFPSIIYSMSIRR
c B9R (1–21) 3.3 32 50 1,890 6 230 nd E
g
321(4) LYNKYSFKLILAEYIRHRNTI A46R (85–105) 2.7 34 31 185 6 50 Y E/L
g
322(6) IFKNNDVRTLLGLILFVLALY A17L (54–74) 2.6 34 33 1,270 6 90 Y L
323(7) AVHLIIYYQLAGYILTVLGLG A38L (216–236) 2.5 34 31 2,170 6 190 Y E/L
g
325(5) MNSLSIFFIVVATAAVCLLFI A28L (1–21) 2.3 36 49 580 6 50 Y L
326(2) LGGGTPIGIISAQVLSEKFTQ J6R (920–940) 2.2 33 25 29 6 8Y E L
327(1) GKTTQCMNIMESIPANTIKYL A48R (39–59) 2.1 33 42 11 6 3n d E L
328(4) DFFKFSFMYIESIKVDRIGDN A20R (211–231) 2.7 32 27 140 6 20 nd E
329(1) HSCKVKIVPLDGNKLFNIAQR D5R (312–332) 2.6 34 11 5 6 1 nd E/L
332(5) MKVVIVTSVASLLDASIQFQK F16L (1–21) 2.4 32 51 380 6 28 nd E/L
g
333(4) IKRGLFFLRLSANLFESQVSS H4L (458–478) 2.3 34 35 68 6 14 Y L
334(3) EDSEYLFRIVSTVLPHLCLDY A10L (14–34) 2.1 35 51 45 6 8Y L
335(3) WKGIYTYRIIKSSFPVPTIKS I6L (335–355) 2.3 35 44 38 6 11 Y E/L
g
336(4) ATAAVCLLFIQGYSIYENYGN A28L (12–32) 2.2 31 15 280 6 40 Y L
337(2) SYDMFNLLLMKPLGIEQGSRI A44L (255–275) 2.6 29 49 28 6 6n d E
338(6) IDNGSNMLILNPTQSDSGIYI B16R (78–98) 2.0 34 44 980 6 170 nd L
g
339(5) KRLPYDMYIIHGKVLDIDEIL I8R (415–484) 1.9 34 36 210 6 45 Y L
341(2) ISEPVNVYLLAAVYSDFNDEV
c D6R (464–484) 2.2 33 47 32 6 2Y L
342(4) IDNESGWKTLVSRAIDLSSKK
c D11L (549–569) 3.3 34 34 130 6 10 Y L
343(5) TWNEASLRQIVGRAIRLNSHV D11L (464–484) 3.2 33 42 210 6 20 Y L
344(3) ITTWPKFRVVKPNSFTFSFSS A24R (174–194) 2.2 32 36 33 6 5Y E L
345(1) FEDQLVFNSISARALKAYFTA I1L (4–24) 3.1 34 28 8 6 0.3 Y L
aPeptides for which HLA-DR-restricted immune responses were observed (Table 3) are underlined.
bPredicted epitopes are shown in bold italic.
cSequences shown are from the MVA strain, with underlined amino acids indicating positions of sequence differences in strains WR and 3737 (representative of Dryvax sequence(s)). For
peptide 310, there is a deletion (A71,L72) and a point mutation (A74V) in the predicted epitope in strain 3737 relative to MVA. Peptides 307 (K70Q), 319 (R21Q), and 342 (K568N) show
changes outside the predicted epitope in strain WR, and peptides 301 (R20K), 307 (K70Q), and 341 (P467S) show changes outside the best predicted epitope for strain 3737.
dNumber of HLA-DR alleles (from a total of 51) predicted to bind an epitope in the peptide, as predicted by ProPred [50].
eY as reference in [62–64,67], in case of peptide 223 Y as in [94]; nd, not detected in the virion.
fExpression pattern as reported by Poxvirus server (http://www.poxvirus.org/): E, early; I, intermediate; L, late.
gPredicted expression pattern as reported by Poxvirus server (http://www.poxvirus.org/).
doi:10.1371/journal.ppat.0030144.t002
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þ T Cell Epitopes from Vaccinia Virusvaccinia-exposed donors. T cells from four donors were used
to map the response in this pool. Peptides 334 and 335 were
recognized by T cells from four and three donors, respec-
tively (Figure 4C). The remaining peptides, 302, 316, and 344,
were recognized at relatively high levels only by donor SL107.
Two of these peptides, 302 and 316, were weakly recognized
by SL131 after a second in vitro expansion (Figure S2).
Although peptide 335 was tested at the same concentration in
isolation and in the pool, the numbers of cells of volunteer
SL107 responding to this peptide is greater than the number
of cells responding to the pool, suggesting that some type of
peptide competition is occurring in the pooled peptide
experiments. This effect is also observed in responses to
peptides from pools 4 and 5.
Pool 4. This pool is recognized by all of the immunized
donors. For two of the immunized donors and the infected
donor, peptide 301 accounts most of the response in this pool
(Figure 4D). As before, donor SL107 recognize all the
peptides in this pool, although signiﬁcantly lower numbers
of T cells are observed when compared with the numbers in
response to peptides in pool 3 (Figure 4C). Donor SL135 has a
small, but positive response to peptide 342 and a weak
response to peptide 336. This last peptide is also weakly
recognized by donor SL131. A second in vitro expansion of
the SL131, SL135, and SL136 reveals responses to peptides
321, 336, and 342 in the TCL from donor SL135.
Pool 5. This pool is recognized by all of the vaccinia-
exposed donors and consequently we evaluated the IFN-c
response from volunteers SL131, SL107, SL135, and SL136. In
this case, peptide 332 accounts for most of the response in all
the donors (Figure 4E). A weak response to peptide 313 is
observed in SL135 TCL, while SL107 TCL presents weak
Table 3. Haplotype of Donors and Exposure to Vaccinia Virus
Donor DRB1 DRB3,4,5 DQA1 DQB1 DPA1 DPB1 Exposure to
Vaccinia Virus
Number of
Exposures
Time since
Exposure (Years)
a
SL101 08/1101 or 08/13 DRB3 ND
b 0301/0603 01/0201 0201/0401 or /01802 Immunization 1 ;35
SL107 03/15 DRB3 DRB5 ND
b 0201/0602 01/01 0401/2301 Immunization 2 35, 1
SL127 01/15 DRB5 0101/0102 0501/0602 01/201 0101/0401 No 0 0
c
SL131 0101/0407 DRB4 0101/0301 0302/0501 0103/01 0301/0402 or /1402 Immunization 2 35, ,1
d
SL135 0401/07 DRB4 0201/0301 0202/0302 01/0103 0301/0401 or /1402 Immunization 1 5
SL136 07/1368 DRB3 DRB4 0103/0201 0202/0603 01/01 ND
b Laboratory infection 2 6
e
SL137 0901/1302 DRB3 DRB4 0102/0302 03/0604 01/0202 0401/0501 No 0 0
c
SL139 0101/0405 DRB4 ND
b 05011/02 ND
b ND
b No 0 0
c
SL140 07 DRB4 ND
b ND
b ND
b ND
b No 0 0
c
aLapse of time between last exposure to the virus and the time at which blood samples were obtained for T cell assays.
bND, not determined.
c0, not immunized.
dBlood samples were obtained from donor SL131 at 7, 13, and 39 d post second immunization.
eDonor SL136 was accidentally infected twice while handling vaccinia virus (WR strain). The route of infection for the first incident was not determined. The second infection occurred a
year later by accidental inoculation with a needle. The viral load of this second inoculation was calculated by the donor to be ;10
6 pfu.
doi:10.1371/journal.ppat.0030144.t003
Figure 3. TCLs Raised from Vaccinia Immune Donors Recognize Pools of Predicted HLA-DR1-Binding Peptides
(A) IFN-c ELISPOT response of vaccinia-specific TCLs from DR1
þdonors to pools of predicted peptides. TCL were generated from PBMCs obtained from a
non-immunized (gray bars) or immunized (dark bars) DR1
þdonor by stimulation with a crude preparation of heat-inactivated vaccinia virus. After 15 to
20 d of in vitro expansion, cells were tested in an IFN-c ELISPOT assay using autologous PBMCs as APCs and the peptide pools as antigen. T cell assays
were performed in cRPMIþ10% human serum (see Materials and Methods).
(B) Kinetics of the IFN-c ELISPOT response in the immunized DR1 donor after a boosting immunization: shown are the T cell responses to the peptide
pools for TCLs generated from blood samples obtained at the indicated time points.
(C) Recognition of peptide pools by TCLs generated from PBMCs obtained from five non-DR1 donors: three immunized (SL101, SL107, and SL135), one
accidentally infected with the vaccinia virus WR strain (SL136), and one non-immunized (LS 137).
doi:10.1371/journal.ppat.0030144.g003
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þ T Cell Epitopes from Vaccinia Virusresponses to this and the remaining peptides in the pool. As
before, a second in vitro expansion conﬁrmed some of the
weak responses in the pool. In this manner, IFN-c responses
to peptide 313 are observed in SL131 and to peptide 325 in
donors SL131 and SL135 (Figure S2).
Pool 6. This peptide pool is recognized strongly by the
infected donor SL136 and at a low level by two of the
immunized volunteers. We consequently mapped the re-
sponse in SL136 (Figure 4F). The response to this pool is
directed mainly to peptide 338, with a minor component to
peptides 319 and a weak response to peptide 322. Responses
to peptide 332 were conﬁrmed after a second in vitro
expansion of the TCLs (Figure S2).
In summary, we have observed that with the exception of
pool 3, in which three peptides are recognized by multiple
donors at relatively high levels, the responses in the pools
were dominated mainly by a single peptide: peptide 345 in
pool 1, peptide 337 in pool 2, peptide 301 in pool 4, peptide
332 in pool 5, and peptide 338 in pool 6. Responses to the
remaining peptides in these pools were signiﬁcantly weaker
or absent. These immunodominant peptides exhibited a
range of afﬁnities in our competition binding assays,
consistent with the idea that other factors besides peptide–
MHC afﬁnity inﬂuence immunodominance patterns [51–53].
Validation of the Approach Using Additional Peptide
Pools
To validate the combination binding/presentation predic-
tion approach used in the initial selection of epitopes for
testing, we utilized a second set of 53 synthetic peptides with
Figure 4. Fine Specificity of TCLs Generated in Vaccinated and Infected Donors
Fine specificities were determined by IFN-c ELISPOT using as antigen individual peptides included in a given pool. (A) Peptide pool 1; (B) peptide pool 2;
(C) peptide pool 3; (D) peptide pool 4; (E) peptide pool 5; and (F) peptide pool 6. Background responses (wells in which peptide was not added) were on
average less than 22 spots per 10
6 cells (range 2 to 34).
doi:10.1371/journal.ppat.0030144.g004
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region (group H) of the predicted peptide binding and
presentation plot (Table S1; Figure 5A), and evaluated these
for recognition by twice-stimulated TCLs from SL131, SL135,
or SL136 donors. Peptides were selected from three regions
of the plot: high antigen presentation prediction score
(Syfpeithi . 25, group P), high HLA-DR1 binding predicted
score (P9 . 0, group B), and both low predicted binding and
low presentation scores (Syfpeithi , 20 and P9 , 1.9, group
N). The peptides, which ranged from 13 to 20 residues in
length and derived from 19 different vaccinia proteins, were
tested in pools of three peptides, with positive responses
deconvoluted as described above for the original set of
peptides (Figure 5B and 5C). None of the 16 group B peptides
were recognized by TCLs from SL131, SL135, or SL136
donors. One of the 17 group P peptides (B7055) and two of
the ten group N peptides (COM2L03 and COM2L09) were
recognized by TCL from DR1
þ donor SL131. Volunteers
SL135 and SL136 do not recognize any peptide in this new
set. These values can be compared with much more efﬁcient
identiﬁcation of the peptides from the original set of
peptides scoring highly in both algorithms, for which 19 of
36 peptides were recognized by TCLs from the same donors
(Table 4). Moreover, of the three low-scoring peptides
Figure 5. Validation of the Prediction Algorithm and Recognition of Vaccinia Peptides That Fell outside the Boundaries of the High Score Region for
Binding and Presentation
(A) HLA-DR1 predicted binding and predicted antigen presentation scores are shown for each 9-mer potential peptide epitope from the vaccinia
genome, Open circles indicate peptides tested and closed red circles indicate peptides for which T cell responses were observed. This graph includes
the 36 peptides presented in Figure 2 and the set of 53 peptides used to validate the prediction algorithm. Peptides are clustered according to their
binding and presentation scores into groups H, P, B, and N. Only three peptides outside the H region are recognized by T cells.
(B) IFN-c ELISPOT responses of SL131, SL135, and SL136 TCLs to pools of peptides included in P, B, or N regions.
(C) Deconvolution of the IFN-c response of SL131 TCL day 0 (gray bars) and day 13 (solid bars) to positive pools.
doi:10.1371/journal.ppat.0030144.g005
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þ T Cell Epitopes from Vaccinia Virusrecognized by SL131 TCL, only one (B7055) bound with
appreciable afﬁnity to HLA-DR1 in a competition assay (IC50
11 nM, unpublished data).
Using both the original high-scoring peptides and the low-
scoring group P, B, and N peptides, the predictive power of
the combined binding and prediction algorithm can be
assessed. Examination of the distribution of observed
epitopes in the binding and presentation dot plot (Figure
5A) reveals that the combination of both binding and
prediction scores is more indicative of peptide recognition
by T cells than is either score used alone. This point is
substantiated by a variety of descriptive statistics calculated
for generous cutoff scores of P9 . 0 and Syfpeithi . 25
(which each select ;5% of all potential epitopes) (Table S2).
In each case, the combination scores were narrowly higher
than either P9 or Syfpeithi alone. Similar results were
observed for other choices of cutoff scores (not shown). The
area under the ROC curve takes into account all possible
cutoff criteria, and for this statistic as well the combination
scores better than either P9 or Syfpeithi alone (Table S2). The
combination P9 . 0 and Syfpeithi . 25 also scored narrowly
higher than single combined values based on the product or
the sum of P9 and Syfpeithi values (Table S2). Thus, the
epitope identiﬁcation approach described here efﬁciently
identiﬁes T cell epitopes, with the combination of both
binding and prediction algorithms superior to the use of
either alone.
MHC Restriction
The peptide sequences in the present study were selected
based on predicted binding and presentation scores for HLA-
DRB1*0101 molecules. We observed responses to these
peptides in individuals that do not carry this allele. In order
to investigate if DRB1*0101 (DR1) was in fact presenting the
vaccinia peptide in SL131, a DR1
þ donor, we studied the
presentation of peptides 301, 302, 305, 325, 332, 334, and 335
by peptide-pulsed homozygous LG2 Epstein–Barr virus
(EBV)-B cells to SL131 TCL day 13 (Figure S3). LG2 cells
and SL131 share only DRB1*0101 and DQB1*0501 (Figure
S4), and we observed that all the peptides were presented by
LG2 cells. Antibodies to DR, but not anti-MHC class I
antibodies, inhibit the presentation of these peptides,
suggesting presentation by MHC DRB1*0101 (DR1). Restric-
tion of peptides 301, 325, and 332 was corroborated by using
additional antigen-presenting cells (APCs) that share other
class II molecules with SL131 (Figure S4). Cell lines lacking
DR1 exhibited a signiﬁcantly reduced presentation, indicat-
ing that responses to peptides 301, 325, and 332 in donor
Table 4. Vaccinia-Derived T Cell Epitopes
Peptide Number Protein Protein Function/Location Sequence Conservation
a Recognized by Donor
b
301 F17R DNA binding phosphoprotein C, CM, M, VAR, E SL107, SL131, SL135, SL136
302 D1R Large subunit of mRNA capping enzyme C, CM, M, VAR, E SL107, SL131
c
305 J2R Thymidine kinase C, CM, M, VAR, E SL131
c
308 F1L Unknown C, CM, VAR (SL131
d), (SL135
d)
313 E8R Membrane protein. Associates with IV/IMV and cores. C, CM, M, VAR, E, MD SL107, (SL131
d), SL135
314 I7L Viral protease, cleavages of viral membrane and core proteins C, CM, M, VAR, E (SL131
d)
316 D6R Early transcription factor, VETF-1 C, CM, M, VAR, E, S, Y SL107, (SL131)
319 B9R Intracellular protein, unknown function C, M (SL136)
321 A46R Toll/IL1 receptor (TIR)-like; suppresses TIR-dependent signal transduction C, CM, VAR, E SL107, (SL135)
322 A17L The p21 membrane protein of vaccinia virus C, CM, M, VAR, E, H SL136
325 A28L IMV membrane protein required for membrane fusion C, CM, M, VAR, E SL107, (SL131), (SL135)
327 A48R Putative; thymidylate kinase C, CM, M, VAR, E (SL131)
328 A20R Viral DNA polymerase processivity factor C, CM, M, VAR, E, H SL107
332 F16L Putative 26.5-kDa protein, unknown function CM, VAR, E SL107, SL131, SL135, SL136
333 H4L RNA polymerase associated protein (RAP 94) C, CM, M, VAR, E, Y, F SL107, SL135
d
334 A10L Major core protein 4a C, CM, VAR, E SL107, SL131, SL135, SL136
335 I6L Telomere-binding protein C, CM, M, VAR, E SL107, SL131, SL135
d
336 A28L IMV membrane protein required for membrane fusion C, CM VAR, E SL107, (SL131), (SL135)
337 A44L Hydroxysteroid dehydrogenase C, CM, M, VAR, E, H SL136
338 B16R IL-1 b inhibitor CM, M, VAR SL136
339 I8R RNA helicase C, CM, M, VAR, E, H SL107, (SL135
d)
342 D11L Nucleoside triphosphate phosphohydrolase I, DNA C, CM, M, VAR, E SL107, SL135
343 D11L Nucleoside triphosphate phosphohydrolase I, DNA C, CM, M, VAR, E, H SL107
344 A24R RNA polymarase subunit rpo 132 C, CM, M, VAR, E SL107, SL135, (SL136
d)
345 I1L Encapsidated DNA-binding protein CM, M, VAR, E SL131, SL135
B7055 F17R Putative DNA-binding phosphoprotein in virus core C, CM, M, VAR, E SL131
d,e
COM2L03 M2L Unknown C, CM, M, VAR, SL131
d,e
COM2L09 M2L Unknown C, CM, M, VAR, SL131
d,e
aRelated poxviruses which identity over 95% was observed in the indicated peptide sequence: C – cowpox virus; CM – camelpox virus; M – monkeypox virus; VAR – variola virus; E –
ectromelia virus; MD – mule deer pox virus; Y – Yaba-like disease virus; S – swinepox virus; F – fowlpox virus; H – horsepox virus. Italics indicate changes in the peptide flanking regions
outside the predicted epitopes shown in Table 1.
bResponses were considered positive if number of primary TCL showed an average .200 specific cells/million (.10 spots/well over background by ELISPOT assay) and at least 10-fold
greater than background response (wells without peptide) and at least 3-fold greater than the standard deviation of triplicate measurements. Weaker responses, .80 specific spots/million
.2-fold/background and .2 sigma, are shown in parentheses.
cPositive by intracellular cytokine staining only.
dResponse observed only after a secondary stimulation in vitro.
eTCL not tested after primary stimulation.
doi:10.1371/journal.ppat.0030144.t004
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to be also presented to T cells in this TCL in the context of
other class II molecules, since EBV-B 9273 cells sharing
DRB4*, DQB1*0501, and DPB1*0301 with donor SL131 also
were able to activate T cells.
Detection of Vaccinia-Specific T Cells in Peripheral Blood
Samples
For tracking immunity induced by vaccination, it would be
useful to be able to detect T cell responses directly in
circulating PBMCs without the need for in vitro expansion
and extended culture. To evaluate whether T cell responses to
the vaccinia peptides were detectable directly ex vivo in
PBMCs from vaccinia-immune donors, we used IFN-c
ELISPOT assays and the same peptide pools as before.
Signiﬁcant T cell responses were observed for PBMCs from
both donors SL135 (immunized) and SL136 (infected) to
peptides in pools 3, 4, and 5, with SL135 PBMCs also
recognizing pool 1 and SL136 also recognizing pool 6 (Figure
6A). This is the same pattern as observed for the TCL raised
from these same donors (Figure 3C). PBMCs were analyzed at
several time points after boosting immunization for the DR1
þ
donor SL131 (Figure 6B). Responses were observed to pools 1,
3, 4, and 5, with the responses to pools 4, 5, and especially 6
increased on day 13 following the second immunization
(Figure 6B). However, by day 39, PBMCs response to this pool
and the others fall to their original levels at day 7. Overall, the
vaccinia-speciﬁc T cells observed in the ex vivo ELISPOT assay
represent only a small fraction of the total population of T
cells present in the PBMC samples, corresponding to ;ﬁve to
20 cells per million for the long-term memory responses and
up to ;50 cells per million shortly after re-immunization.
The ELISPOT assay does not distinguish CD4
þ and CD8
þ T
cell responses, and potentially both could contribute to the
observed response. To conﬁrm the role of CD4
þ T cell, new
samples of PBMCs were obtained, depleted of CD8
þ T cells,
and subject to a short stimulation with a crude preparation of
heat-inactivated vaccinia virus (or medium alone) before IFN-
c ELISPOT analysis. For this study we obtained PBMCs from
the vaccinia-exposed donors SL135 and SL136 and from two
non-immunized donors, SL139 and SL140. After depletion,
the number of CD8
þ T cells in these preparations was
reduced to less than 0.31% (Figure S5). Figure 6C–6F shows
the responses to a set of ten peptides that includes the
dominant peptides in the pools and as a negative control a
peptide representing the inﬂuenza virus hemagglutinin HA
peptide [54]. PBMCs from SL135 have signiﬁcant responses to
peptide 345 (pool 1), peptides 334 and 335 (pool 3), and
peptide 332 (pool 5) (Figure 6E). T cells from donor SL136 or
the non-immunized donors SL139 and SL140 do not have
statistically signiﬁcant responses to any of the peptides
evaluated by this assay (Figure 6C, 6D, and 6F). In summary,
CD4
þ T cell IFN-c responses to three vaccinia peptides could
be observed in PBMC samples from an immunized donor
immediately after booster immunization, but also many years
after exposure to the virus.
Discussion
Vaccinia virus is the central component of the smallpox
vaccine, used in the only successful eradication of an
infectious disease (reviewed in [55]). Concerns about the
potential use of smallpox virus as a biological weapon,
combined with a high morbidity rate and contraindications
to immunization with vaccinia virus in some segments of the
population, and recent outbreaks of monkeypox and other
related poxviruses [56,57], all highlight the need for a new
generation of smallpox vaccines [58,59]. For these reasons,
new strains of vaccinia virus have been developed [60,61] and
subunit vaccines for smallpox are in development [11,12].
However, advancement in this ﬁeld is hampered by the lack of
well-characterized CD4
þ T cell epitopes required for the
induction of long-lasting cellular and humoral immune
responses.
We approached the challenge of identifying CD4
þ T cell
epitopes in vaccinia using an algorithm that combines
independent assessments of MHC–peptide afﬁnity [23,25]
and propensity for MHC-mediated antigen presentation [33].
These two algorithms each proved highly predictive in an
evaluation of 18 well-characterized HLA-DR1-restricted
immunodominant epitopes. The combination approach was
extremely effective in identifying vaccinia-derived CD4
þ T
cell epitopes. Of 36 potential epitopes tested, we observed
IFN-c responses to 25 peptide sequences, with strong
responses in multiple donors observed for ten peptides. By
comparison, in a recent study .2,000 peptides were screened
to identify only 14 epitopes [20]. The 25 peptides for which
we observed T cell responses were derived from 23 proteins
(A28L and D11L had two epitopes each). These proteins
represent a mixture of early, late, and intermediate proteins,
and include proteins present in the virion as well as proteins
expressed only in infected cells (Table 3).
Peptides 301 and 334, which were recognized by all of our
vaccinia-immune donors, are derived from proteins F17R and
A10L, respectively, proteins that have been reported to be
among the very most abundant proteins in the intracellular
mature virion particles [62]. A CD4
þ T cell response to a
different region of protein A10L was recently reported [18].
Peptides 342 (D11L), 343 (D11L), 344 (A24R), and 302 (D1R)
are all derived from enzymes involved in nucleic acid
metabolism, and which are also highly represented in vaccinia
virions. Ten other epitopes also derive from proteins present
in vaccinia virions (IMV), but are reported to be at lower
abundance [62–64]. We used a crude lysate of infected cells as
a source of vaccinia virus antigens for in vitro ampliﬁcation
of TCLs, and so we expected that our experimental protocol
would allow identiﬁcation of T cell responses directed against
proteins present in viral particle and also against proteins not
present in the virus but which are expressed in infected cells.
Six peptides (305, 319, 328, 332, 337, and 338) derive from
proteins not reported to be present in vaccinia virions.
Peptide 332, derived from putative protein F16L, is recog-
nized by all the vaccinia-exposed donors, but is not present in
puriﬁed virions [62–64]. Two peptides, 337 and 338, are
derived from the immunomodulatory and virulence factors
A44L (hydroxysteroid dehydrogenase) [65] and B16R (IL-1 b
inhibitor) [66], and also are not expected to be present in the
virion. Interestingly, we observed preferential responses to
these epitopes in the infected as compared to vaccinated
donors. However, inter-individual variation in the T cell
responses to vaccinia virus as reported by Jing et al. could also
explain these observations [18]. T cell responses to peptides
306, 308, 314, and 327 were only evident after a second in
vitro expansion. These peptides belong to the proteins I8R,
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and I7L, containing 314, are present in the virion. DR-
restricted CD4
þ T cell responses to proteins I8R and A48R
have been reported to other regions of these proteins [18].
Envelope proteins A27L, A33R, B5R, and L1R have
attracted attention as possible subunit vaccine candidates
because antibodies against these proteins correlate with
protection against viral challenge in animal models [12]. We
tested two peptides derived from L1R (312 and 317), but did
not observe responses in our donors. Both A33R and B5R
have at least one peptide with very favorable HLA-DR1
binding prediction and antigen presentation scores that,
however, fell just outside the range that we tested, and both of
these proteins as well as L1R have additional peptides with
scores in a slightly more generous region. Additional testing
will be required to determine whether these high-scoring
sequences do elicit the CD4
þ T cell responses observed in
these proteins. A27L does not contain potential epitopes that
score highly by this algorithm. Although responses to A27L,
A33R, B5R, and L1R were not observed among the set of
Figure 6. Ex Vivo IFN-c Response of T Cells in Peripheral Blood to Vaccinia Peptides
Response in PBMCs isolated from vaccinia-exposed donors and from non-exposed donors to pools of vaccinia peptides or individual peptides,
measured by IFN-c ELISPOT.
(A) IFN-c responses of PBMCs in an immunized donor (SL135) and in an infected donor (SL136). No spots were observed in control wells (cRPMIþ10%
HS, no peptide). (B) Kinetics of the IFN-c response after a boosting immunization of donor SL131, a DR1 donor. Spots for control wells (cRPMIþ10% HS,
no peptide) day 7 4þ/ 1, day 13 1þ/ 1, and day 39 0þ/ 0 (C–F) IFN-c responses in PBMCs after depletion of CD8
þ T and overnight incubation in
cRPMIþ10% HS (gray bars) or incubation in cRPMIþ10% HS supplemented with a crude preparation of heat-inactivated vaccinia virus (solid bars). (C, D)
non-immunized donors SL139 and SL140. (E, F) vaccinia-immunized donors SL135 and SL136. Spots in control wells (Medium, no peptide) 25þ/ 20.
Statistically significant responses (p ,0.05) indicated by an asterisk.
doi:10.1371/journal.ppat.0030144.g006
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(peptides 322, 325, and 338) from three other proteins
expected to be present on the virion membrane, A17L (p21
membrane protein), A28L (IMV membrane protein required
for membrane fusion), and F16L (IL-1 b inhibitor). A17L is
reported to be present in the inner of the two membranes of
the IMV particles, with the N-terminus of the protein
protruding to the surface of the particle, and antibodies
raised against the exposed fraction of the protein neutralize
vaccinia virus [67]. These proteins might be considered as
possible candidates for inclusion in subunit vaccine develop-
ment efforts. Finally, antibody responses have been reported
for protein I1L, containing peptide 345, and protein A10L,
containing peptide 334 [9]. However, there is currently no
information about the possible role of these antibodies in
immunity to vaccinia.
Only very recently have CD4
þ T cell epitopes been
identiﬁed in vaccinia virus [17–20]. Jing et al. [18] reported
human T cell responses to 35 vaccinia proteins, and Moutaftsi
et al. [20] reported murine T cell responses to 13 vaccinia
proteins. In this study, we detected in total human T cell
responses to 28 peptide sequences from 24 different proteins,
including the peptides with low prediction scores. T cell
responses deﬁned in this study and the ones reported by Jing
et al. [18] have in common only the response to three
proteins, with no overlap in the actual peptide epitopes
recognized. Comparison of the human T cell responses
reported in our study and the murine responses reported
by Moutaftsi et al. reveals a partial overlap in the T cell
response to peptide 328, and a complete overlap in the
response to peptides 325 and 345 in the proteins A20R, A28L,
and I1L, respectively. Tang et al. [17] reported human
responses to three A27L epitopes in T cells isolated from
blood samples obtained after 1 month or 3 years of
vaccination; no epitopes from this protein were identiﬁed
in our study or in the studies of Jing et al. [18] or Moutaftsi et
al. [20]. Finally, using the same set of peptides tested here,
Mitra-Kaushik et al. [19] reported cytotoxic CD4
þ T cell to
D1R (MVA302) and A24R (MVA341) peptides, for which we
observed robust IFN-c responses. Whether the difference
between these reports reﬂect individual (‘‘private’’) patterns
of immunodominance, differences between the TCL and
assay protocols used by the different groups, or incomplete
sampling of a broad response to many different antigens,
remains to be established by further work.
An important factor to consider in the characterization of
T cell epitopes is the sequence conservation, since viral
variation potentially can evade T cell immunity. Current
vaccines induce substantial cross-protection between poxvi-
rus family members. The 35 peptide sequences presented in
this study are highly conserved among vaccinia strains, with
only peptides 301 and 310 exhibiting variation within the
core epitope or the immediately ﬂanking residues (Table 1).
The epitope sequences also are conserved within the larger
poxvirus family (Table 3). Peptides 301, 332, 334, 335, 344,
and 345, which each were recognized by strong responses in
at least two of the donors in our study, are conserved in at
least three poxvirus, including the human pathogens variola
(all peptides) and monkeypox (all but 332). CD4
þ T cells
recognizing three of these peptides (332, 334, and 345) were
observed in PBMCs from a vaccinated donor, indicating that
cells with these speciﬁcities make up a signiﬁcant part of the
long-lasting memory pool elicited by immunization with
vaccinia virus.
Our identiﬁcation of highly conserved CD4
þT cell epitopes
derived from vaccinia virus and recognized by donors of
multiple MHC haplotypes could aid efforts to track cellular
immunity induced by next-generation smallpox vaccines and
could contribute to selection of candidate proteins for
inclusion in potential subunit vaccine approaches. The
epitope identiﬁcation algorithm described here appears to
be a signiﬁcant improvement over current approaches, and
c o u l dﬁ n da p p l i c a t i o ni np r e d i c t i o no fc l a s sI IM H C -
restricted T cell responses to other large-genome viral and
bacterial pathogens.
Materials and Methods
Peptide synthesis. Peptides were synthesized by Genemed Syn-
thesis using standard Fmoc chemistry and were characterized by high
performance liquid chromatography (HPLC) using a Vydac-C18
reverse phase column and by MALDI-TOF mass spectrometry. All
peptides were .80% pure as judged by HPLC and exhibited
molecular masses consistent with the expected sequence.
Vaccinia virus. Vaccinia virus (Dryvax) stocks were propagated and
provided by John Cruz (University of Massachusetts Medical School).
This virus was expanded in CV-1 cells, titrated, and stored at  80 8C
as previously reported [68]. For T cell assays and for in vitro
expansion of T cells, lysate of CV-1 infected cells was treated at 60 8C
for 1 h to inactivate the virus [69].
Epitope prediction. Translated poxvirus genome sequences were
obtained from the Poxvirus Bioinformatics Resource Center (http://
www.poxvirus.org/). HLA-DR1 (DRB1*0101) binding epitopes were
predicted using the genomic sequences of vaccinia virus strain MVA
[39]. In some cases, epitopes were compared to orthologs in the
vaccinia virus strains WR and 3737. The latter strain was isolated
from a vaccinia lesion following vaccination with Dryvax, and is used
an exemplar of Dryvax component strain(s). Predictions for non-
vaccinia protein in Figure 1 and Table 1 used sequences from the
National Center for Biotechnology Information (NCBI) as indicated.
Syfpeithi, P9, P10, undec, and Epimmune predictions were per-
formed using position-speciﬁc scoring matrices and local software (C.
Parry and L. J Stern, unpublished data). The Sypfeithi matrix for the
prediction of antigen processing and presentation by HAL-DR1 was
obtained from the Syfpeithi server (http://www.syfpeithi.de/) [33]. For
the Syfpeithi algorithm, scores can potentially range from 0 to 42; for
all nine-residue sequences in the MVA translated genome, the
average score was 11.9 (standard deviation 7.3). The P9 matrix for
prediction of peptide binding to HLA-DR1 was obtained by
modiﬁcation of the virtual DR1 matrix originally described by
Sturniolo et al. [38]. For the dominant pocket P1 [25,70,71], a simple
aromatic/aliphatic/other proﬁle was used: Trp, Tyr, and Phe were
assigned a value of 0, Ile, Leu, Val, and Met a value of 1, and all other
residues assigned  5. This proﬁle is similar to but more permissive
than that incorporated into the original virtual matrix motif [38].
Proﬁles of the major pockets at P4, P6, P7, and P9 were retained from
the virtual matrix [38]. The proﬁles at the minor pocket P2 and P3
positions were obtained from a full matrix originally determined for
DR4 [23], since these pockets are essentially identical in DR1 and
DR4. Finally, P5 and P8 proﬁles were set to 0 for all residues (these
side chains make no or minimal contact with HLA-DR [47]). For this
algorithm scores can potentially range from 16.6 to 6.4; for all nine-
residue sequences in the MVA translated genome the average score
was  5.3 (standard deviation 2.9). This algorithm has been imple-
mented on the epitope prediction server RCDEV (http://rcdev.
umassmed.edu/nwpredict.php), and a similar matrix has been
implemented in ProPred (http://www.imtech.res.in/raghava/propred/).
For the P10 matrix, an additional column was added to the P9 matrix
using values from an analysis of the speciﬁcity in the P10 pocket [72].
Values for the ‘‘Undeca’’ 11-mer and ‘‘Epimmune’’ 9-mer matrices
were taken from references [24] and [48], respectively. The matrix-
based IEDB [73] and Rankpep [74] predictions were performed using
their respective web servers http://immuneepitope.org/home.do and
http://bio.dfci.harvard.edu/RANKPEP/. Hidden Markov model HMM
[29] and artiﬁcial neural network ANN [29] predictions both were
performed using the Multpred web server (http://research.i2r.a-star.
edu.sg/multipred/), with values for HLA-DR1 used. Potential epitopes
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(http://www.imtech.res.in/raghava/propred/) [50], which implements
the virtual class II matrix algorithm of Sturniolo et al. [38] for many
DR alleles.
Statistical methods. The intrinsic predictive capabilities of the
predictive algorithms were characterized using the area under the
receiver operating characteristics curve (AUC ROC) [35,36]. Algo-
rithms were compared using the AUC ROC, and product of
sensitivity and speciﬁcity for each algorithm using the cutpoint at
which that product is maximized. The product of sensitivity and
speciﬁcity is the probability of correctly classifying a randomly
selected true positive and true negative [75].
Protein expression and puriﬁcation. For peptide binding experi-
ments, the extracellular portion of HLA-DR1 was produced by
expression of isolated subunits in Escherichia coli inclusion bodies
followed by refolding in vitro as described previously [76]. Refolded
HLA-DR1 was puriﬁed by immunoafﬁnity chromatography using the
conformation-speciﬁc monoclonal antibody LB3.1, followed by gel
ﬁltration chromatography in phosphate-buffered saline (pH 6.8). The
protein concentration was measured by UV absorbance at 280 nm
using e280 of 54,375 M
 1 cm
 1 for empty HLA-DR1.
Peptide binding assays. A competition assay was used to determine
binding afﬁnities of peptides to HLA-DR1 molecule. Peptide-free
HLA-DR1 produced in E. coli (25 nM) was mixed together with
biotinylated Ha(306–318) peptide probe (Habio, 25 nM) and varying
concentrations of unlabelled competitor peptide (10
 12 to 10
 5 M).
The mixtures were incubated for 3 d at 37 8C in 100 mM sodium
phosphate buffer (pH 5.5), containing protease inhibitors and 0.5 mg/
ml octylglucoside, followed by detection of bound biotinylated
peptide using an immunoassay that employed anti-DR1 capture
antibody LB3.1 and alkaline phosphatase-labeled streptavidin. IC50
values were obtained by ﬁtting a binding curve to the plots of
absorbance versus concentration of competitor peptide.
Human donors and haplotype determination. Nine healthy adult
volunteers, three females and six males, were selected as donors for
the present study. Informed consent and previous history of vaccinia
immunization or infection was obtained from the donors prior to
blood collection under a protocol approved by the Medical School
Institutional Review Board of the University of Massachusetts. HLA
class II haplotype was performed by the UMass MHC haplotyping
core facility using PCR-based protocols.
T cell lines. TCLs were generated from blood samples obtained by
venipuncture using sodium heparin as anticoagulant. Brieﬂy, after
puriﬁcation by density centrifugation over Ficoll-Hypaque (Pharma-
cia), PBMCs were resuspended in cRPMIþ10% HS (RPMI 1640
supplemented with 10% human ABþserum, 100 U/ml penicillin, 100
lg/ml streptomycin, 1 mM sodium pyruvate, 2 mM L-glutamine, and 1
mM non-essential amino acids [GIBCO]) and 1 million cells (in 0.5 ml)
were dispensed in each of six wells of a 24-well plate. Subsequently, an
equal volume of a heat-inactivated lysate (60 8C for 1 h) of CV-1 cells
infected with vaccinia virus in cRPMIþ10% HS, originally containing
1.7 3 10
7 pfu/ml, was added per well. After 72 h, cultures were
supplemented with 1 ml of cRPMI þ100 U/ml IL-2 (NCI BRB
Preclinical Repository). Cells expansion proceeded for approximately
17 d in cRPMIþ10% HS supplemented with 100 U/ml IL-2. TCL
prepared by this method are predominately CD4
þ(92–99% CD4
þ, see
Figure S4).
ELISPOT assay. Recognition of peptides was evaluated by IFN-c
ELISPOT using either autologous PBMCs or EBV-B cells lines as
APCs, TCLs or PBMCs as a source of T cells and peptides or a crude
preparation of heat-inactivated vaccinia virus as a source of antigen.
Cells and antigens, in cRPMIþ10% HS, were incubated overnight
(;15 h) in plates treated as indicated by the manufacturer (BD
Biosciences). Number of IFN-c-secreting cells was determined using
an ELISPOT analyzer equipped with ImmunoSpot 3.2 software (CTL
analyzers). Responses were considered positive if a primary TCL
showed an average .200 speciﬁc spots/million T cells (.10 spots/well
over background) and a speciﬁc response at least 10-fold greater than
the background response (wells without peptide) and at least 3-fold
greater than the standard deviation of duplicate measurements.
Weaker responses were deﬁned as .80 speciﬁc spots/million .2-fold/
background and .2 s the standard deviation of duplicate measure-
ments.
Depletion of CD8
þ T cells and IFN-c ESLIPOT. CD8
þ T cells were
depleted from fresh PBMC samples by incubation of the samples with
anti-CD8
þ Miltenyi beads according to the manufacturer. After
depletion, a sample of the CD8
þ-depleted PBMCs was removed for
FACS analysis to verify the depletion. The CD8
þ-depleted cells were
divided into two fractions. One of the fractions was incubated
overnight with a crude preparation of heat-inactivated vaccinia virus,
as described in the TCL section, and a second one in medium. The
following day, non-adherent cells were recovered and assessed by
IFN-c ELISPOT using as antigen peptides as indicated before.
Flow cytometry. For T cell phenotype determinations, T cells were
washed twice with FACS buffer (PBS þ 1% BSA þ 0.02% NaN3) and
stained for 30 min with ﬂuorescent antibodies (Pharmingen/BD
Bioscience). Stained cells were washed with FACS buffer, ﬁxed with
1% paraformaldehyde, and analyzed on a four-color BD FACSCali-
bur.
Genetic restriction and EBV-B cell lines. Genetic restriction of the
T cell responses was deﬁned by using EBV-B cell lines sharing one or
more MHC molecules with the immunized DR1 donor and by
inhibition of the antigen presentation with anti-MHC antibodies. For
antigen presentation assays, EBV-B cells were pulsed with peptide,
washed, and used as APCs in an ELISPOT assay. Cell lines (haplotypes
shown in Figure S4) were obtained from the ATCC or IHWG Cell
Bank (http://www.ihwg.org/cellbank/). For antibody blocking experi-
ments, peptide-pulsed APCs were incubated with antibodies to MHC
molecules. Subsequently, antibody and peptide were removed by
washing and cells were used as APCs in an ELISPOT assay. Afﬁnity-
puriﬁed antibodies to MHC class I (W6/32) and DR molecules (LB3.1)
were used in this study.
Supporting Information
Figure S1. ROC Curves for Epitope Prediction Algorithms and
Known HLA-DR1-Restricted T Cell Epitopes
ROC curves show the tradeoff between sensitivity and speciﬁcity as
the positive criterion value is varied. The diagonal line in each plot
shows the ROC curve expected for a random guess. The ROC curve
for a 100% accurate test would be a straight line corresponding to the
left vertical axes and the top horizontal axis. Areas under the curves
with standard errors are shown in Table 1.
Found at doi:10.1371/journal.ppat.0030144.sg001 (57 KB PDF).
Figure S2. Responses of TCLs Stimulated Twice In Vitro
Recognition of vaccinia peptides by TCLs SL131 day 13, SL135, and
SL136 after a second in vitro expansion with heat-inactivate lysate of
CV-1 cells infected with Dryvax vaccinia virus. The bars indicate the
number of speciﬁc IFN-c producing cells by ELISPOT (mean spots in
wells with peptide minus mean spots in wells without peptide) using
as antigen individual peptides included in a given pool and
autologous PBMCs as APCs. (A) Peptide pool 1; (B) peptide pool 2;
(C) peptide pool 3; (D) peptide pool 4; (E) peptide pool 5; and (F)
peptide pool 6. Background responses (wells in which peptide was not
added) for donor SL131 1,023þ/ 72, donor SL135 23þ/ 12, donor
SL136 37þ/ 24 on average per 1310
6 cells. Responses are considered
positive, weak, or negative as described in Table 4.
Found at doi:10.1371/journal.ppat.0030144.sg002 (34 KB PDF).
Figure S3. T Cell Responses Observed in a TCL from the DR1 Donor
SL131 to Peptides 301, 302, 305, 332, 334, and 335 Are Mediated by
DR Molecules
Inhibition of antigen presentation by antibodies to class I (W6/32)
and to DR (L243). LG2 cells, sharing DRB1*0101 and DQB1*0501
with donor SL131, were pulsed with the indicated peptides and
subsequently incubated on ice with antibodies to class I (gray bar) or
DR (dark bars). After removal of peptide and antibody, cells were
used as APCs to evaluate the response of a TCL from DR1 donor
SL131 by IFN-c ELISPOT. The values represent the percentage in the
reduction of the numbers of spots, when compared to cells not
treated with antibodies. The average and standard deviation number
of spots in wells without antibody are: peptide 301 2,320þ/ 30,
peptide 302 1,400þ/ 280, peptide 305 1,520þ/ 240, peptide 332
1,945þ/ 107, peptide 334 2,873þ/ 387 and peptide 335 2,640þ/ 244.
ND, not done.
Found at doi:10.1371/journal.ppat.0030144.sg003 (9 KB PDF).
Figure S4. T Cell Responses Observed in a TCL from the DR1 Donor
SL131 to Peptides 301, 325, and 332 Are Primarily Restricted to DR1
APCs
Presentation of peptides 301, 325, and 332 by peptide-pulsed EBV-
transformed B-LCLs is shown: 9273 (gray bars) sharing DRB4 and
DQB1*0501; 9030 (blue bars) sharing DRB1*0407 and DRB4; 9380
(red bars) sharing DQB1*0501 and 9040 (yellow bars) do not present
efﬁciently peptides 301, 325, and 332 to a TCL derived from donor
SL131. In contrast, Hom-2 cells, sharing DR1 and DQB1*0501, are
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Category Name NCBI GenBank MVA Gene Description
Source proteins for
DR1 test epitopes
Influenza virus heamagglutinin strain A/
New York/383/2004(H3N2)
gij72582085 gbjAAZ74540.1
Human triose phophate isomerase (TPI) gij339841 gbjAAB59511.1
Tetanus toxin (TT) gij135624 gbjP04958
N. meningitidis outer membrane porin A protein gij89276847 gbjABD66613.1
EBV nuclear antigen EBNA-1 gij710394 gbjAAA67286.1
Hepatitis C virus strain LIV23 polyprotein gij111283662 gbjABH09187.1
Dengue virus type 4 polyprotein precursor gij12018170 gbjAAG45435.1
HIV-1 (strain HXB2) p24 gag epitopes gij77416881 gbjP04585
HIV-1 strain NY-5 p24 gag protein gij328432 gbjAAB04036.1
Human cytomegalovirus (strain AD169) pp65 gij130714 gbjP06725
M. leprae heat shock protein hsp65 gij116243 gbjP09239
EBV BZLF-1 protein gij115196 gbjP03206
Vaccinia virus genomes Modified vaccinia Ankara (MVA) gij2772662 gbjU94848.1
Western reserve (WR) gij66275797 gbjNC_006998.1
3737 (Dryvax) gij88900616 gbjDQ377945.1
Vaccinia virus proteins A9L gij47088448 gbjAAT10518.1 MVA120L IMV membrane protein
A10L gij2772723 gbjAAB96462.1 MVA121L Major core protein P4a
A17L gij2772729 gbjAAB96468.1 MVA128L IMV membrane protein morphogenesis factor
A20R gij2772784 gbjAAB96523.1 MVA132R Putative 49.1-k protein
A24R gij2772787 gbjAAB96526.1 MVA135R RNA polymerase subunit rpo132
A28L gij2772734 gbjAAB96473.1 MVA139L Putative 16.3-k protein
A29L gij2772735 gbjAAB96474.1 MVA140L RNA polymerase subunit rpo35
A31R gij2772788 gbjAAB96527.1 MVA142R Putative 14.4-k protein
A38L gij2772738 gbjAAB96477.1 MVA149L Putative 31.5-k protein
A44L gij2772740 gbjAAB96479.1 MVA157L Hydroyxsteroid dehydrogenase
A46R gij2772799 gbjAAB96538.1 MVA159R Putative 27.6-k protein
A47L gij2772741 gbjAAB96480.1 MVA160L Putative 27.6-k protein
A48R gij2772800 gbjAAB96539.1 MVA161R Thymidylate kinase
A9L gij2772722 gbjAAB96461.1 MVA120L Putative 10.5-k protein
B12R gij2772814 gbjAAB96553.1 MVA180R Protein kinase
B16R gij2772816 gbjAAB96555.1 MVA184R Interleukin-1 beta receptor
B18R gij2772817 gbjAAB96556.1 MVA186R 68-k ankyrin-like protein
B9R gij2772811 gbjAAB96550.1 MVA177R Putative 8.3-k protein
C10L gij2772663 gbjAAB96402.1 MVA006L Putative 37.9-k protein
D11L gij2772712 gbjAAB96451.1 MVA108L Nucleoside triphosphate phosphohydrolase I
D1R gij2772772 gbjAAB96511.1 MVA098R mRNA capping enzyme large subunit
D5R gij2772775 gbjAAB96514.1 MVA102R Putative 90.4-k protein
D6R gij2772776 gbjAAB96515.1 MVA103R VETF-1 early transcription factor
E2L gij2772688 gbjAAB96427.1 MVA049L Putative 85.9-k protein
E3L gij2772689 gbjAAB96428.1 MVA050L dsRNA-dependent PK inhibitor
E5R gij2772747 gbjAAB96486.1 MVA052R Putative 39.1-k protein
E6R gij2772748 gbjAAB96487.1 MVA053R Putative 66.7-k protein
E8R gij2772750 gbjAAB96489.1 MVA055R Putative 31.9-k protein
F15L gij2772685 gbjAAB96424.1 MVA045L Putative 18.6-k protein
F16L gij2772686 gbjAAB96425.1 MVA046L Putative 26.5-k protein
F17R gij2772746 gbjAAB96485.1 MVA047R 11-k DNA-binding phosphoprotein
F1L gij2772673 gbjAAB96412.1 MVA029L Putative 25.9-k protein
G1L gij2772701 gbjAAB96440.1 MVA070L Putative 68-k protein
H3L gij2772708 gbjAAB96447.1 MVA093L IMV membrane-associated protein
H4L gij2772709 gbjAAB96448.1 MVA094L RAP 94
H5R gij2772769 gbjAAB96508.1 MVA095R VLTF-4 late transcription factor
H6R gij2772770 gbjAAB96509.1 MVA096R DNA topoisomerase 1
I1L gij2772694 gbjAAB96433.1 MVA062L Putative 35.9-k protein
I2L gij2772695 gbjAAB96434.1 MVA063L Putative 8.5-k protein
I4L gij2772697 gbjAAB96436.1 MVA065L Ribonucleotide reductase large subunit
I6L gij2772699 gbjAAB96438.1 MVA067L Putative 43.5-k protein
I7L gij2772700 gbjAAB96439.1 MVA068L Topoisomerase II
I8R gij2772752 gbjAAB96491.1 MVA069R NPH-II helicase
J2R gij2772764 gbjAAB96503.1 MVA086R Thymidine kinase
J6R gij2772767 gbjAAB96506.1 MVA090R RNA polymerase subunit
K3L gij2772671 gbjAAB96410.1 MVA024L IFN resistance eIF-2a homolog
K1L gij335353 gbjAAA48005.1 — Putative protein
L1R gij2772759 gbjAAB96498.1 MVA080R 25 myristylated IMV virion protein
L2R gij2772760 gbjAAB96499.1 MVA081R Putative 10.3-k protein
M2L gij 335352 gbjAAA48004.1 — Putative protein
doi:10.1371/journal.ppat.0030144.t005
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peptide-pulsed 9273 cells, suggesting a low response mediated by
either DRB4 or DQ molecules.
Found at doi:10.1371/journal.ppat.0030144.sg004 (41 KB PDF).
Figure S5. Phenotype of Vaccinia-Speciﬁc TCL and Analysis of
PBMCs Depleted from CD8
þ T Cells
(A) Shown are representative dot plots for the phenotypic analysis of
TCLs elicited to heat-inactivated vaccinia virus. T cells were washed
and stained with the combination of CD3-FITC/CD4-APC antibodies,
or the combination of CD3-FITC/CD8-APC antibodies. TCLs from
donor SL131 day 0 (pre-boosting immunization) and day 13 (13 d post
boosting immunization) are shown. TCLs from the immunized donor
SL135 and the infected donor SL136 are also shown. (B) Determi-
nation of the number of CD8þ T cells in PBMCs from non-
immunized donors SL139 and SL140 and from vaccinia-exposed
donors SL135 and SL135 after magnetic depletion of CD8þT cells. T
cells were washed and stained with the combination of CD8-PE/CD4-
APC.
Found at doi:10.1371/journal.ppat.0030144.sg005 (90 KB PDF).
Table S1. Low Scoring Vaccinia Peptides Accession Numbers
Found at doi:10.1371/journal.ppat.0030144.st001 (135 KB DOC).
Table S2. Statistical Analysis of Approaches Used to Predict Vaccinia
Epitopes
Found at doi:10.1371/journal.ppat.0030144.st002 (39 KB DOC).
Accession Numbers
The GenBank (http://www.ncbi.nlm.nih.gov/Genbank/) and NCBI
(http://www.ncbi.nlm.nih.gov/) protein sequences used in this study
are presented in Table 5. The Protein Data Bank (http://www.rcsb.org/
pdb/) accession numbers are inﬂuenza virus heamagglutinin (A/New
AYork/383/2004(H3N2) (1DLH), mutated TPI(23–37) from human
triose phophate isomerase (1KLG), and HIV-1 strain NY-5 gag p24
protein (1SJE).
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